These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 1238569

  • 1. Cholinergic effects of molecular segments of apomorphine and dopaminergic effects of N,N-dialkylated dopamines.
    Ginos JZ, Cotzias GC, Tolosa E, Tang LC, LoMonte A.
    J Med Chem; 1975 Dec; 18(12):1194-1200. PubMed ID: 1238569
    [Abstract] [Full Text] [Related]

  • 2. Adenosine 3',5'-cyclic monophosphate as a possible mediator of rotational behaviour induced by dopaminergic receptor stimulation in rats lesioned unilaterally in the substantia nigra.
    Satoh H, Satoh Y, Notsu Y, Honda F.
    Eur J Pharmacol; 1976 Oct; 39(2):365-77. PubMed ID: 185065
    [Abstract] [Full Text] [Related]

  • 3. Dopaminergic antagonists: effects of 1,2,3,4-tetrahydroisoquinoline and its N-methyl and N-propyl homologs on apomorphine- and L-dopa-induced behavioral effects in rodents.
    Ginos JZ, Doroski D.
    J Pharmacol Exp Ther; 1979 Apr; 209(1):79-86. PubMed ID: 571017
    [Abstract] [Full Text] [Related]

  • 4. Apomorphine-induced rotation in normal rats and interaction with unilateral caudate lesions.
    Jerussi TP, Glick SD.
    Psychopharmacologia; 1975 Apr; 40(4):329-34. PubMed ID: 1096216
    [Abstract] [Full Text] [Related]

  • 5. AF64A lesions of mouse striatum result in ipsilateral rotations to D2 dopamine agonists but contralateral rotations to muscarinic cholinergic agonists.
    Zhou LW, Zhang SP, Connell TA, Weiss B.
    J Pharmacol Exp Ther; 1993 Feb; 264(2):824-30. PubMed ID: 8094754
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of dopamine-stimulated adenylate cyclase activity in rat caudate after lesions in substantia nigra: evidence for denervation supersensitivity.
    Mishra RK, Gardner EL, Katzman R, Makman MH.
    Proc Natl Acad Sci U S A; 1974 Oct; 71(10):3883-7. PubMed ID: 4372596
    [Abstract] [Full Text] [Related]

  • 7. The central effects of a novel dopamine agonist.
    Setler PE, Sarau HM, Zirkle CL, Saunders HL.
    Eur J Pharmacol; 1978 Aug 15; 50(4):419-30. PubMed ID: 568069
    [Abstract] [Full Text] [Related]

  • 8. Opposing effects of dopaminergic to cholinergic compounds on a cerebral dopamine-activated adenylate cyclase.
    Tang LC, Cotzias GC.
    Proc Natl Acad Sci U S A; 1977 Feb 15; 74(2):769-73. PubMed ID: 265541
    [Abstract] [Full Text] [Related]

  • 9. Stereotyped behaviour after cholinergic, but not dopaminergic, stimulation of the substantia nigra in rats.
    Decsi L, Nagy J, Zámbó K.
    Life Sci; 1978 Jun 05; 22(21):1873-8. PubMed ID: 566832
    [No Abstract] [Full Text] [Related]

  • 10. Inhibition of nigral dopaminergic firing by N-n-propyl-norapomorphine: behavioural and biochemical correlates.
    Mereu G, Argiolas A, Melis MR, Gessa GL.
    Ann Ist Super Sanita; 1982 Jun 05; 18(1):57-61. PubMed ID: 6892092
    [No Abstract] [Full Text] [Related]

  • 11. Dopaminergic effects of non-hydroxylated rigid analogs of apomorphine.
    Rusterholz DB, Long JP, Flynn JR, Cannon JG, Lee T, Pease JP, Clemens JA, Wong DT, Bymaster FP.
    Eur J Pharmacol; 1979 Apr 01; 55(1):73-82. PubMed ID: 571341
    [Abstract] [Full Text] [Related]

  • 12. Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
    Wolfarth S.
    Pol J Pharmacol Pharm; 1976 Apr 01; 28(5):469-93. PubMed ID: 796834
    [No Abstract] [Full Text] [Related]

  • 13. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.
    Johnson AM, Loew DM, Vigouret JM.
    Br J Pharmacol; 1976 Jan 01; 56(1):59-68. PubMed ID: 943193
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99.
    Martin GE, Haubrich DR, Williams M.
    Eur J Pharmacol; 1981 Nov 19; 76(1):15-23. PubMed ID: 7318920
    [Abstract] [Full Text] [Related]

  • 15. Aporphines, 21. (1,2) Dopaminergic activity of aporphine and benzylisoquinoline derivatives. Synthesis of 8-hydroxyaporphines and 1-(hydroxybenzyl)-2-n-propyl-1,2,3,4-tetrahydroisoquinolines.
    Costall B, Naylor RJ.
    J Med Chem; 1977 Feb 19; 20(2):190-6. PubMed ID: 556776
    [Abstract] [Full Text] [Related]

  • 16. A-69024: a non-benzazepine antagonist with selectivity for the dopamine D-1 receptor.
    Kerkman DJ, Ackerman M, Artman LD, MacKenzie RG, Johnson MC, Bednarz L, Montana W, Asin KE, Stampfli H, Kebabian JW.
    Eur J Pharmacol; 1989 Aug 03; 166(3):481-91. PubMed ID: 2509217
    [Abstract] [Full Text] [Related]

  • 17. Aporphines. 15. Action of aporphine alkaloids on dopaminergic mechanisms in rat brain.
    Miller RJ, Kelly PH, Neumeyer JL.
    Eur J Pharmacol; 1976 Jan 03; 35(1):77-83. PubMed ID: 943290
    [Abstract] [Full Text] [Related]

  • 18. Influence of dopamine-like compounds on stereotypy and locomotor activity in atropinized rats.
    Grabowska M.
    Arch Immunol Ther Exp (Warsz); 1975 Jan 03; 23(6):753-61. PubMed ID: 1241267
    [Abstract] [Full Text] [Related]

  • 19. Esters of apomorphine and N,N-dimethyldopamine as agonists of dopamine receptors in the rat brain in vivo.
    Baldessarini RJ, Walton KG, Borgman RJ.
    Neuropharmacology; 1975 Oct 03; 14(10):725-31. PubMed ID: 1238952
    [No Abstract] [Full Text] [Related]

  • 20. Stereotyped and circling behaviour induced by dopaminergic agonists after lesions of the midbrain raphe nuclei.
    Costall B, Naylor RJ.
    Eur J Pharmacol; 1974 Dec 03; 29(2):206-22. PubMed ID: 4613561
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.